This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?
by Kinjel Shah
LLY's Mounjaro and Zepbound drove 56% of revenues in 2025 as obesity demand surged, with new launches and Medicare access set to fuel growth.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
pharmaceuticals
Top Stock Reports for Costco, Roche & Lam Research
by Mark Vickery
Costco's resilient membership model, strong cash flow and e-commerce momentum position it to weather market turmoil and keep earnings growing.
RHHBYPositive Net Change GRMNNegative Net Change SYKPositive Net Change LRCXNegative Net Change EQTPositive Net Change COSTPositive Net Change IDTPositive Net Change SPRUNegative Net Change
computers pharmaceuticals retail semiconductor utilities
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel
by Zacks Equity Research
Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.
BMYPositive Net Change GILDPositive Net Change ACLXNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026
by Kinjel Shah
LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
pharmaceuticals
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?
by Sundeep Ganoria
With Amtagvi sales surging but shares down 46%, can Iovance's growth runway outshine Rigel's strong 2025 rally?
SNYPositive Net Change LLYPositive Net Change RIGLNegative Net Change IOVAPositive Net Change
biotechs medical pharmaceuticals
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?
by Ahan Chakraborty
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
TBPHPositive Net Change CRMDNegative Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bull of the Day: Cardinal Health (CAH)
by Bryan Hayes
This company serves nearly 90% of US hospitals and delivers more than 43,000 pharmaceutical shipments daily.
CAHPositive Net Change
cancer dividends earnings hospitals investing medical medical-devices oncology-screening pharmaceuticals smart-health
Zacks Market Edge Highlights: MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace
by Zacks Equity Research
MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace hit 5-year highs as double-digit 2026 earnings growth fuels a new "Magnificent" list.
CATNegative Net Change WMTPositive Net Change LLYPositive Net Change MTZPositive Net Change HWMPositive Net Change
aerospace construction industrial-products pharmaceuticals retail
What's in Store for These 5 Medical Companies This Earnings Season?
by Ahan Chakraborty
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
IRWDNegative Net Change NVAXNegative Net Change NTLANegative Net Change VTRSNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Stock to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
VTRS gears up for Q4 results amid Indore import alert, segment revenue pressure and steady margins as shares surge 39.7% in a year.
AMRXNegative Net Change CSTLNegative Net Change VTRSNegative Net Change TERNPositive Net Change
biotechnology biotechs medical pharmaceuticals